DOI QR코드

DOI QR Code

Multiple Cytotoxic Factors Involved in IL-21 Enhanced Antitumor Function of CIK Cells Signaled through STAT-3 and STAT5b Pathways

  • Rajbhandary, S. (Department of Hematology, Tianjin First Central Hospital) ;
  • Zhao, Ming-Feng (Department of Hematology, Tianjin First Central Hospital) ;
  • Zhao, Nan (Department of Hematology, Tianjin First Central Hospital) ;
  • Lu, Wen-Yi (Department of Hematology, Tianjin First Central Hospital) ;
  • Zhu, Hai-Bo (Department of Hematology, Tianjin First Central Hospital) ;
  • Xiao, Xia (Department of Hematology, Tianjin First Central Hospital) ;
  • Deng, Qi (Department of Hematology, Tianjin First Central Hospital) ;
  • Li, Yu-Ming (Department of Hematology, Tianjin First Central Hospital)
  • Published : 2013.10.30

Abstract

Background/Objectives: Maintenance of cellular function in culture is vital for transfer and development following adoptive immunotherapy. Dual properties of IL-21 in activating T cells and reducing activation induced cell death led us to explore the mechanism of action of IL-21 enhanced proliferation and cytotoxic potential of CIK cells. Method: CIK cells cultured from PBMCs of healthy subjects were stimulated with IL-21 and cellular viability and cytotoxicity to K562 cells were measured. To elucidate the mechanism of action of IL-21, mRNA expression of cytotoxic factors was assessed by RT-PCR and protein expression of significantly important cytotoxic factors and cytokine secretion were determined through flow cytometry and ELISA. Western blotting was performed to check the involvement of the JAK/STAT pathway following stimulation. Results: We found that IL-21 did not enhance in vitro proliferation of CIK cells, but did increase the number of cells expressing the CD3+/CD56+ phenotype. Cytotoxic potential was increased with corresponding increase in perforin ($0.9831{\pm}0.1265$ to $0.7592{\pm}0.1457$), granzyme B ($0.4084{\pm}0.1589$ to $0.7319{\pm}0.1639$) and FasL ($0.4015{\pm}0.2842$ to $0.7381{\pm}0.2568$). Interferon gamma and TNF-alpha were noted to increase ($25.8{\pm}6.1ng/L$ to $56.0{\pm}2.3ng/L$; and $5.64{\pm}0.61{\mu}g/L$ to $15.14{\pm}0.93{\mu}g/L$, respectively) while no significant differences were observed in the expression of granzyme A, TNF-alpha and NKG2D, and NKG2D. We further affirmed that IL-21 signals through the STAT-3 and STAT-5b signaling pathway in the CIK cell pool. Conclusion: IL-21 enhances cytotoxic potential of CIK cells through increasing expression of perforin, granzyme B, IFN-gamma and TNF-alpha. The effect is brought about by the activation of STAT-3 and STAT-5b proteins.

Keywords

References

  1. Allard EL, Hardy MP, Leignadier J, et al (2007). Over expression of IL-21 promotes massive CD8+ memory T cell accumulation. Eur J Immunol, 37, 3069-77. https://doi.org/10.1002/eji.200637017
  2. Brandt K, Bulfone-Paus S, Jenckel A, et al (2003). Interleukin-21 inhibits dendritic cell-mediated T cell activation and induction of contact hypersensitivity in vivo. J Invest Dermatol, 121, 1379-82. https://doi.org/10.1046/j.1523-1747.2003.12603.x
  3. Burchill MA, Goetz CA, Prlic M, et al (2003). Distinct Effects of STAT5 Activation on CD4+ and CD8+ T Cell Homeostasis: Development of CD4+CD25+ Regulatory T Cells versus CD8+ Memory T Cells. J Immunol, 171, 5853-64. https://doi.org/10.4049/jimmunol.171.11.5853
  4. Burgess SJ, Marusina AI, Pathmanathan I, Borrego F, Coligan JE (2006). IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells. J Immunol, 176, 1490-7. https://doi.org/10.4049/jimmunol.176.3.1490
  5. Davis ID, Brady B, Kefford RF, et al (2009). Clinical and biological efficacy of recombinant human interleukin21 in patients with stage IVmalignant melanoma without prior treatment:a phase IIa trial. Clin Cancer Res, 15, 2123-9. https://doi.org/10.1158/1078-0432.CCR-08-2663
  6. Decker T, Bogner C, Oelsner M, Peschel C, Ringshausen I (2010). Antiapoptotic effect of interleukin-2 in B-CLL cells with low and high affinity IL-2 receptors. AnnHematol, 89, 1125 -32.
  7. Gattinoni L, Klebanoff CA, Restifo NP (2012). Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer, 12, 71-84.
  8. Golay J, Manganini M, Facchinetti V, et al (2003). Rituximab-mediated antibody dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica, 88, 1002-12.
  9. Gowda A, Roda J, Hussain SR, et al (2008). IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood, 111, 4723-30. https://doi.org/10.1182/blood-2007-07-099531
  10. Hand TW, Cui W, Jung YW, et al (2010). Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival. Proc Natl Acad Sci U S A, 107, 16601-6. https://doi.org/10.1073/pnas.1003457107
  11. Kasaian MT, Whitters MJ, Carter LL, et al (2002). IL-21 Limits NK Cell Responses and Promotes Antigen-Specific T Cell Activation. Immunity, 16, 559-69. https://doi.org/10.1016/S1074-7613(02)00295-9
  12. Kortylewski M, Kujawski M, Wang T, et al (2005). Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med, 11, 1314-21. https://doi.org/10.1038/nm1325
  13. Lee CK, Rao DT, Gertner R, et al (2000). Distinct requirements for IFNs and STAT1 in NK cell function. J Immunol, 165, 3571-7. https://doi.org/10.4049/jimmunol.165.7.3571
  14. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS (2005). A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant, 11, 181-7. https://doi.org/10.1016/j.bbmt.2004.11.019
  15. Moroz A, Eppolito C, Li Q, et al (2004). IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol, 173, 900-9. https://doi.org/10.4049/jimmunol.173.2.900
  16. Novy P, Huang X, Leonard WJ, Yang Y (2011). Intrinsic IL-21 signaling is critical for CD8 T cell survival and memory formation in response to vaccinia viral infection. J Immunol, 186, 2729-38. https://doi.org/10.4049/jimmunol.1003009
  17. Oh HM, Yu CR, Golestaneh N, et al (2011). STAT3 protein promotes T-cell survival and inhibits interleukin-2 production through up-regulation of Class O Forkhead transcription factors. J Biol Chem, 286, 30888-97. https://doi.org/10.1074/jbc.M111.253500
  18. Olioso P, Giancola R, Di Ritti M, et al (2009). Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol, 27, 130-9. https://doi.org/10.1002/hon.886
  19. Ozaki K, Spolski R, Ettinger R, et al (2004). Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol, 173, 5361-71. https://doi.org/10.4049/jimmunol.173.9.5361
  20. Parmigiani A, Pallin MF, Schmidtmayerova H, Lichtenheld MG, Pahwa S (2011). IL-21 and cellular activation concurrently induce potent cytotoxic function and promote antiviral activity in human CD8 T cells. Hum Immunol, 72, 115-23. https://doi.org/10.1016/j.humimm.2010.10.015
  21. Parrish-Novak J, Dillon SR, Nelson A, et al (2000). Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature, 408, 57-63. https://doi.org/10.1038/35040504
  22. Pievani A, Borleri G, Pende D, et al (2011). Dual-functional capability of CD3+CD56+CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood, 18, 3301-10.
  23. Quigley M, Huang X, Yang Y (2008). STAT1 signaling in CD8 T cells is required for their clonal expansion and memory formation following viral infection in vivo. J Immunol, 180, 2158-64. https://doi.org/10.4049/jimmunol.180.4.2158
  24. Rankin AL, MacLeod H, Keegan S, et al (2011). IL-21 receptor is critical for the development of memory B cell responses. J Immunol, 186, 667-74. https://doi.org/10.4049/jimmunol.0903207
  25. Strengell M, Matikainen S, Siren J, et al (2003). IL-21 in synergy with IL-15 or IL-18 enhances IFN-Y production in Human NK and T cells. J Immunol, 170, 5464-9. https://doi.org/10.4049/jimmunol.170.11.5464
  26. Timmerman JM. Byrd JC, Andorsky DJ, et al (2012). Efficacy and safety of recombinant interleukin-21 (rIL-21) and rituximab in relapsed/refractory indolent lymphoma. Clin Cancer Res, 18, 5752-60. https://doi.org/10.1158/1078-0432.CCR-12-0456
  27. Thompson JA, Curti BD, Redman BG, et al (2008). Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol, 26, 2034-9. https://doi.org/10.1200/JCO.2007.14.5193
  28. Verneris MR, Karami M, Baker J, Jayaswal A, Negrin RS (2004). Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood, 103, 3065-72. https://doi.org/10.1182/blood-2003-06-2125
  29. Welte T, Zhang SS, Wang T, et al (2003). STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc Natl Acad Sci U S A, 100, 1879-84. https://doi.org/10.1073/pnas.0237137100
  30. Yi JS, Du M, Zajac AJ (2009). A vital role for interleukin-21 in the control of a chronic viral infection. Science, 324, 1572-6. https://doi.org/10.1126/science.1175194
  31. Yue FY, Lo C, Sakhdari A, et al (2010). HIV-specific IL-21 producing CD4+ T cells are induced in acute and chronic progressive HIV infection and are associated with relative viral control. J Immunol, 185, 498-506. https://doi.org/10.4049/jimmunol.0903915
  32. Zeng R, Spolski R, Casas E, et al (2007). Mechanism of IL-21 mediated proliferation. Blood, 109, 4135-42. https://doi.org/10.1182/blood-2006-10-054973
  33. Zhao MF, Deng Q, Li YM, et al (2007). Interleukin 21 enhances the expansion and anti-tumor cytotoxic activity of cytokine-induced killer cells derived from both peripheral blood and cord blood in vitro. Blood, 110, 4887b. (Ash meeting abstract)

Cited by

  1. An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells vol.14, pp.7, 2014, https://doi.org/10.1517/14712598.2014.900537
  2. Impact of Allogenic and Autologous Transfusion on Immune Function in Patients with Tumors vol.15, pp.1, 2014, https://doi.org/10.7314/APJCP.2014.15.1.467
  3. Interleukin-18 Synergism with Interleukin-2 in Cytotoxicity and NKG2D Expression of Human Natural Killer Cells vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7857
  4. Adoptive Immunotherapy for Small Cell Lung Cancer by Expanded Activated Autologous Lymphocytes: a Retrospective Clinical Analysis vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1487
  5. Association Study of Single-Nucleotide Polymorphisms of STAT2/STAT3/IFN-γ Genes in Cervical Cancer in Southern Chinese Han Women vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3117
  6. Comparative study of different procedures for the separation of peripheral blood mononuclear cells in cytokine-induced killer cell immunotherapy for hepatocarcinoma vol.36, pp.4, 2015, https://doi.org/10.1007/s13277-014-2837-5
  7. Suicide gene-modified killer cells as an allogeneic alternative to autologous cytokine-induced killer cell immunotherapy of hepatocellular carcinoma vol.13, pp.3, 2016, https://doi.org/10.3892/mmr.2016.4811
  8. Efficient killing of radioresistant breast cancer cells by cytokine-induced killer cells vol.39, pp.3, 2017, https://doi.org/10.1177/1010428317695961
  9. IL-21 Is Positively Associated with Intervertebral Disc Degeneration by Interaction with TNF-α Through the JAK-STAT Signaling Pathway vol.40, pp.2, 2017, https://doi.org/10.1007/s10753-017-0508-6
  10. Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy vol.8, pp.1664-3224, 2017, https://doi.org/10.3389/fimmu.2017.00774